Heather Bumgardner
Adult Health · Port Wentworth, GANPI 1679980668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 616 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,502, 4.2 times the $832 reported in 2021. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 616 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$2K
- Sanofi$1K
- Biocryst US Sales Co., LLC$1K
- Regeneron Healthcare Solutions, Inc.$915
- Novartis$844
- plus $5K from 28 others
What the payments were for
- Consulting fees$540%
- Food & beverage$12,19397%
- Education$3383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $1,552 |
| AstraZeneca | 56 | $1,501 |
| Sanofi | 57 | $1,417 |
| Biocryst US Sales Co., LLC | 98 | $1,246 |
| Regeneron Healthcare Solutions, Inc. | 36 | $915 |
| Novartis | 49 | $844 |
| Pfizer | 41 | $805 |
| GSK | 46 | $802 |
| Optinose US, Inc. | 41 | $591 |
| CSL Behring | 18 | $487 |
| Amgen | 15 | $339 |
| Pharming Healthcare, Inc. | 14 | $281 |
| Grifols USA, LLC | 12 | $280 |
| Octapharma USA, Inc. | 9 | $225 |
| Sanofi-aventis U.S. LLC | 3 | $223 |
| LEO Pharma Inc. | 9 | $205 |
| Kaleo, Inc. | 5 | $107 |
| Hospira, Inc. | 4 | $94 |
| Incyte Corporation | 4 | $92 |
| Genentech USA, Inc. | 3 | $79 |
| Alk-abello, Inc | 3 | $67 |
| Tersera Therapeutics LLC | 2 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| ADMA Biomanufacturing LLC | 2 | $54 |
| Cycle Pharmaceuticals Inc | 3 | $53 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 2 | $27 |
| Bio Products Laboratory USA, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $24 |
| GC Biopharma USA, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Dermavant Sciences, Inc. | 1 | $21 |
| Merck | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,585 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 67 | $270,926 |
| XolairOmalizumab | 25 | $94,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $92,487 |
| Dupixent PenDupilumab | 14 | $53,692 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $26,249 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $21,435 |
| Ipratropium Bromide | 290 | $16,478 |
| Spiriva RespimatTiotropium Bromide | 15 | $12,218 |
| Epinephrine | 62 | $11,867 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $10,569 |
| QnaslBeclomethasone Dipropionate | 13 | $8,694 |
| Desloratadine | 173 | $8,463 |
| Azelastine Hcl | 242 | $8,179 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 36 | $7,949 |
| Mometasone Furoate | 57 | $6,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $802 | $113,922119 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,501 | $36,81866 claims |
| Hikma Pharmaceuticals USAEpinephrine | $23 | $11,86762 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $56 | $8,69413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.
Other adult health in Port Wentworth
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.